pharma is the sole category represented across all 1 tracked stories. National Chemical Defense Consortium is most often covered alongside AI Antidote Development Model, which appears in 1 of these 1 story. Their average consequence score of 7 runs above the beat's 6 for that window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about National Chemical Defense Consortium
pharma is the sole category represented across all 1 tracked stories. National Chemical Defense Consortium is most often covered alongside AI Antidote Development Model, which appears in 1 of these 1 story. Their average consequence score of 7 runs above the beat's 6 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. National Chemical Defense Consortium appears in 1 tracked Biotech story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering National Chemical Defense Consortium. Shared-story counts are live from our verified record — not editorial picks.
Lunai Bioworks (NASDAQ: LNAI) has established the National Chemical Defense Consortium to target U.S. government countermeasure contracts valued up to $1.2 billion. The initiative leverages a proprietary three-year AI-driven development model to accelerate the creation of antidotes for chemical threats.
National Chemical Defense Consortium is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.